Original news and analysis on international IP policy
World Health Organization Director General Margaret Chan today issued a statement attempting to clarify the UN agency's relationship with the industries - like producers of junk food and soda - in line to be regulated as the UN moves to battle globally rising noncommunicable diseases (NCDs) like diabetes, heart disease and cancer.
Richard Elliott writes: Canada’s Access to Medicines Regime (CAMR) was a unanimous pledge by Parliament to help people dying in developing countries because they lack access to affordable medicines. So far, it has delivered only one medicine to one country since Parliament created it more than 8 years ago (in May 2004). CAMR is clearly not working; it needs to be reformed to address the unnecessary deficiencies and limitations that have rendered it cumbersome and user-unfriendly for both developing countries and the manufacturers of lower-cost, generic medicines - the two parties that need to make use of CAMR if patients are to get the medicines they need.
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria appointed Ambassador Mark Dybul, a former US Global AIDS Coordinator, as the new head of the organisation. Additionally, the Board decided to move forward on implementing a new funding model, replacing the rounds-based system.
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announced the identification of three potential drug classes for the treatment of neglected tropical diseases through the availability of hundreds of compounds in the public domain.
Greg Perry, a longtime leader in the European generics industry, has been named the new executive director of the Medicines Patent Pool, a cutting-edge Geneva-based group working to increase access to affordable, high-quality medicines for HIV/AIDS patients in low and middle income countries.
In the recent decision on the case “Novartis AG versus Laboratorios LKM SA re cease of use of patent” the Third Chamber of the Federal Civil and Commercial Appellate Court of Argentina set an important precedent in relation to the interpretation of the ius prohibendi of patent holders. In other words, the demarcation of what they can and cannot prohibit.
The industry practice of extending patent protection on pharmaceuticals by obtaining additional patents on other features of the drug ingredients can lead to decades of delay in generic competition, a new study argues.
World Health Organization members this week achieved consensus on a set of voluntary targets and indicators for the prevention and control of the world’s biggest killers including cancer, diabetes, cardiovascular and chronic respiratory diseases. Two targets and several indicators relate to national health systems response.
The European Union’s global plan for health, development cooperation includes the commitment that high-quality medicines and care in the developing world be available without restrictions. As such, despite its growing impact and strong investment in product R&D, the plan seemingly lacks adequate coherence, innovative financing, and coordination, collaboration with concerned parties. Filling these gaps would be a matter of priority and a way for the EU to achieve indisputable field leadership.
An outside meeting of experts has prepared a report ahead of this month’s gathering of World Health Organization members hoping to agree on new models for financing research and development for diseases lacking adequate market mechanisms and public policies. These include neglected diseases that predominantly affect poor populations unable to pay high prices needed to defray R&D costs under the existing commercial model.
Members of the World Trade Organization intellectual property rights committee today launched their first-ever debate on IP and innovation. In addition, least developed countries formally requested an extension of their transition period to enforce WTO rules on IPRs.
The World Trade Organization member committee on the WTO intellectual property agreement meets tomorrow, with a new agenda item on intellectual property and innovation at the request of the United States and Brazil.